Entera Bio Ltd. Kiryat Hadassah Minrav Building – Fifth Floor Jerusalem 9112002 Israel
January 29, 2018
|
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-3628
Attn: | Ms. Ada D. Sarmento Ms. Mary B. Breslin |
Re: | Entera Bio Ltd. Registration Statement on Form F-1 Registration No. 333-221472 |
Dear Ms. Sarmento and Ms. Breslin,
Reference is made to our letter, filed as correspondence via EDGAR on January 19, 2018, in which we requested the acceleration of the effective date of the above-referenced registration statement for Tuesday, January 23, 2018, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
[Signature Page Follows]
Sincerely,
ENTERA BIO LTD. | ||
By: | /s/ Phillip Schwartz | |
Name: Phillip Schwartz | ||
Title: Chief Executive Officer |
Via EDGAR
CC: Michael Kaplan, Davis Polk & Wardwell LLP
Sophia Hudson, Davis Polk & Wardwell LLP